LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension

2024/10/01 by Jochen Steppan, Huilei Wang, Kavitha Nandakumar +7

paper · doi:10.1152/ajplung.00327.2023

Abstract

Pulmonary arterial stiffening contributes to the progression of PAH and the deterioration of right heart function. This study shows that LOXL2 is upregulated in rat models of PH. LOXL2 inhibition halts pulmonary vascular remodeling and improves PA contractility, endothelial function, and PA pressure, resulting in prolonged survival. Thus, LOXL2 is an important mediator of PA remodeling and stiffening in PH and a promising target to improve PA pressures and survival in PH.

Related

• Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis
• Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension
• Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca2+ signaling
• Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II
• The Metabolic Theory of Pulmonary Arterial Hypertension